{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-024362","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.157937+00:00","generated_at":"2026-06-23T15:02:51.731268+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cardiff Oncology announces ESMO 2022 posters showing onvansertib overcomes irinotecan resistance in RAS-mutated mCRC","bullets":["Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).","Abstract 397P: Early ≥90% decrease in KRAS MAF after one cycle predicts higher ORR and longer PFS in ongoing Phase 1b/2 trial.","Additional findings from EAP and trial data to be released during ESMO, subject to embargo policies.","Conference call and webcast on Sept 12, 2022 at 4:30 PM ET to discuss clinical and corporate update."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-024362","json":"https://secwatch.observer/filing/0001628280-22-024362.json","markdown":"https://secwatch.observer/filing/0001628280-22-024362.md","text":"https://secwatch.observer/filing/0001628280-22-024362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/0001628280-22-024362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022024362/crdf-20220906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T15:02:51.731268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}